Feature | February 06, 2014

Photon-Counting Technique Increases Detection Rate in Screening Mammography

Mammography Systems Women's Health Clinical Study DR CR Radiation Dose

This shows two-view screening mammograms obtained with the DR photon-counting system show a spiculated mass in the right upper quadrants (arrow). The diagnosis was invasive ductal carcinoma, 8 mm in diameter, as seen on the (a) right craniocaudal image, (b) right mediolateral oblique image, and (c) zoomed in craniocaudal image of the lesion.

Mammography Systems Women's Health Clinical Study DR CR Radiation Dose

Two-view screening mammograms obtained with the DR photoncounting system show an indistinct mass in the left lower outer quadrant (arrow). The diagnosis was invasive ductal carcinoma, 7 mm in diameter, as seen on the (a) left craniocaudal image, (b) left mediolateral oblique image, and (c) zoomed in craniocaudal image of the lesion.

Mammography Systems Women's Health Clinical Study DR CR Radiation Dose

Two-view screening mammograms obtained with the DR photoncounting system show pleomorphic calcifications in a linear distribution in the right upper quadrants (arrow). The diagnosis was DCIS, as depicted on the (a) right craniocaudal image, (b) right mediolateral oblique image, and (c) zoomed in craniocaudal image of the lesion.

February 6, 2014 — Digital mammography screening with photon-counting technique offers high diagnostic performance, according to a study published online in the journal Radiology.
 
As mammography screening has shifted to digital technology, a range of computed radiography (CR) and direct radiography (DR) systems have emerged. The photon-counting technique is a DR approach that uses a detector to decrease scattered radiation and noise, enabling dose reduction.
 
"In population-based mammography screening, dose reducing techniques that don't compromise outcome parameters are desirable," said Walter Heindel, M.D., department of clinical radiology at the University Hospital Muenster in Muenster, Germany.
 
For the study, Heindel and colleagues analyzed data from the mammography screening program in North Rhine-Westphalia, the most populous state in Germany. They compared the screening performance of a DR photon-counting scan system with those of statewide operating screening units using different digital technologies. During the study period (2009 to 2010), 13,312 women were examined using the photon-counting system, and 993,822 women were screened with either CR or DR systems alone.
 
The DR photon-counting scan system had a cancer detection rate of 0.76 percent for subsequent screening, compared with 0.59 percent for the other screening units. The recall rate was 5.4 percent for the photon-counting method and 3.4 percent for the other methods.
 
"The higher cancer detection resulting from the use of the DR photon-counting scan system is due to high detection of both small, invasive cancers and ductal carcinoma in situ," Heindel said.
 
The photon-counting technique had almost twice the detection rate of other methods for ductal carcinoma in situ (DCIS), an early, noninvasive form of disease. It had a higher DCIS detection rate than the statewide units and the conventional DR subgroup.
 
In addition, the mean average glandular radiation dose of the DR photon-counting scan system was significantly lower than the conventional DR systems with the individually used parameters of the automatic exposure control.
 
The photon-counting technique also offers lateral dose modulation during the image acquisition, which can help account for differences in breast density. 
 
"One future research direction is the application of spectral imaging for quantification of breast glandular tissue, addressing the problem of breast density," Heindel said.
 
For more information: pubs.rsna.org/journal/radiology

Related Content

News | Nuclear Imaging | June 24, 2016
Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual Meeting of the Society...
PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016
Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
VASH collimator, DOE, molecular breast imaging, SNMMI 2016

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half. Technologies developed at DOE’s Jefferson Lab for the variable angle slant hole collimator are included in two filings to the U.S. Patent and Trademark Office. Image courtesy of DOE’s Jefferson Lab.

News | Breast Imaging | June 21, 2016
Preliminary tests have demonstrated that a new device may enable up to six times better contrast of tumors in the...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and...
Hologic, KLAS Research, Tomosynthesis 2016, Genius 3-D Mammography, Selenia Dimensions
News | Mammography | June 15, 2016
Hologic announced that the company received top marks from U.S. mammography providers in a new independent report from...
hypertrophic cardiomyopathy, HCM, strain echocardiography, risk assessment, ASE 2016
News | Cardiovascular Ultrasound | June 13, 2016
After following a large sub-set of patients, researchers found that by using strain echocardiography they could...
Overlay Init